We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International Convention
June 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag Tech
July 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
Search BIO members.
July 8 - 11, 2019 | Des Moines, Iowa
Revivicor has established a unique line of pigs, GalSafe®, that does not have galactose alpha 1,3 galactose (α-gal) on cells, tissues, or organs. A newly discovered allergy linked to the α-gal epitope, that is present on most mammals including cows and pigs, has been recently declared an epidemic by allergists. The allergy is often referred to as α-gal syndrome or the red meat allergy. At the federal level, the Center for Disease Control (CDC) has recently initiated surveillance activity. The USDA as well as recent scientific publications report that over 25% of selected populations are pre-sensitized to α-gal via a tick bite. Exposure to α-gal from food (meat, gelatin), cosmetics (collagen) and therapeutics (heart valves, pancreatic enzymes, heparin, vaccines) has resulted in adverse events including anaphylaxis. Derivatives from GalSafe® pigs are poised to provide safer and more efficacious products than comparable products derived from conventional source animals.